InflaRx NV (NASDAQ:IFRX)

2.40
Delayed Data
As of Dec 08
 0.00 / 0.00%
Today’s Change
0.78
Today|||52-Week Range
4.99
-49.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$114.5M

Company Description

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Contact Information

InflaRx NV
Winzerlaer Strasse 2
Jena Thueringen 07745
P:493641508180
Investor Relations:

Employees

Shareholders

Other institutional8.48%
Mutual fund holders0.57%
Individual stakeholders--

Top Executives

Niels Christoph RiedemannChief Executive Officer & Executive Director
Thomas TaapkenChief Financial Officer
Renfeng GuoExecutive Director & Chief Scientific Officer
Maria HabelVP, Head-Pre-Clinical Research & Development
Yong LiSenior Director-Research & Development